Loading
Life sciences · Journal article
Small · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Despite the promising potential of Cu-based nanozymes in cancer therapy, the therapeutic efficacy remains limited by the difficulty of achieving controlled Cu-ion release without compromising lattice integrity and catalytic activity. Herein, we developed a therapeutic nanoplatform utilizing bismuth (Bi)-doping techniques to control the release of copper (Cu) ions, enabling synergistic ion interference therapy, chemodynamic therapy (CDT) and photothermal therapy (PTT) for tumor treatment. Based on the instability of Bi-based compounds in the tumor microenvironment (TME), Bi ions are preferentially released from Bi-doped CuS nanosheets (Bi-CuS NSs), exposing more Cu vacancies and facilitating Cu ion release compared to CuS NSs. More importantly, upon cellular internalization, the released copper ions induce ionic homeostasis disruption, leading to cuproptosis in liver cancer cells. Simultaneously, the Cu vacancies generated by ion release enhance the peroxidase-like activity to produce more reactive oxygen species and improve the photothermal conversion efficiency to induce localized hyperthermia, synergistically amplifying tumor cell destruction. Consequently, Bi-CuS NSs exhibit excellent potential for synergistic metal ion interference and photothermal/chemodynamic therapy, enabling the multimodal treatment of hepatocellular carcinoma. This study presents a Bi-mediated strategy for regulating Cu-ion release and catalytic activity in metal-based cancer nanomedicines.